ストックスクリーナーアプリを入手
31.74
4.14%
-1.37
アフターアワーズ：
31.93
0.19
+0.60%
前日終値:
$33.11
開ける：
$33.4
24時間の取引高:
1.86M
Relative Volume:
0.79
時価総額：
$3.69B
収益：
-
当期純損益:
$-472.34M
株価収益率:
-7.6558
EPS:
-4.1459
ネットキャッシュフロー:
$-340.33M
1週間 パフォーマンス:
-8.77%
1か月 パフォーマンス:
-18.64%
6か月 パフォーマンス:
+9.30%
1年 パフォーマンス:
-2.55%
1日の値動き範囲:
$31.48
$33.75
1週間の範囲:
$30.80
$36.12
52週間の値動き範囲:
$22.96
$43.15
Viking Therapeutics Inc Stock (VKTX) Company Profile
名前
Viking Therapeutics Inc
セクター
電話
858-704-4660
住所
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Compare VKTX vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
31.74 | 4.05B | 0 | -472.34M | -340.33M | -4.1459 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-26 | 開始されました | Wolfe Research | Peer Perform |
| 2025-10-29 | 開始されました | Canaccord Genuity | Buy |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 開始されました | Goldman | Neutral |
| 2025-02-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-02-07 | 開始されました | Citigroup | Neutral |
| 2024-12-02 | 開始されました | Piper Sandler | Overweight |
| 2024-11-22 | 開始されました | B. Riley Securities | Buy |
| 2024-11-04 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-09-11 | 開始されました | JP Morgan | Overweight |
| 2024-06-27 | 開始されました | Morgan Stanley | Overweight |
| 2024-05-16 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 繰り返されました | Oppenheimer | Outperform |
| 2024-03-07 | 開始されました | Jefferies | Buy |
| 2024-02-28 | 繰り返されました | Oppenheimer | Outperform |
| 2023-05-31 | 再開されました | ROTH MKM | Buy |
| 2023-03-28 | 繰り返されました | Maxim Group | Buy |
| 2023-03-17 | 開始されました | Stifel | Buy |
| 2021-07-29 | 再開されました | BTIG Research | Buy |
| 2021-05-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 開始されました | BMO Capital Markets | Outperform |
| 2020-05-05 | 開始されました | Chardan Capital Markets | Buy |
| 2020-05-01 | 開始されました | BTIG Research | Buy |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-25 | 開始されました | Stifel | Buy |
| 2019-03-29 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 繰り返されました | Maxim Group | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Mkt Perform |
| 2018-12-12 | 開始されました | B. Riley FBR | Buy |
| 2018-11-19 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 繰り返されました | H.C. Wainwright | Buy |
| 2018-09-18 | 繰り返されました | Maxim Group | Buy |
| 2018-09-18 | 繰り返されました | Raymond James | Outperform |
| 2018-07-20 | 開始されました | SunTrust | Buy |
| 2018-06-28 | 開始されました | Raymond James | Outperform |
| 2018-06-01 | 繰り返されました | Laidlaw | Buy |
| 2018-05-31 | 繰り返されました | Maxim Group | Buy |
| 2018-03-26 | 再開されました | H.C. Wainwright | Buy |
| 2017-11-28 | 繰り返されました | Maxim Group | Buy |
| 2017-11-21 | 開始されました | ROTH Capital | Buy |
すべてを表示
Viking Therapeutics Inc (VKTX) 最新ニュース
Viking Therapeutics (VKTX) Q2 Earnings Preview: Market Pricing i - GuruFocus
Can These 5 Biotech Stocks Beat Wall Street's Q2 Estimates? - Yahoo Finance
Is Viking Therapeutics (VKTX) a Buy as Wall Street Analysts Look Optimistic? - Yahoo Finance
Viking Therapeutics Inc (VKTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
VKTX|Viking Therapeutics Inc|Price:34.880|Chg%:+0.090 - TradingKey
Viking Therapeutics Inc expected to post a loss of $1.25 a shareEarnings Preview - TradingView
Insiders At Viking Therapeutics Sold US$15m In Stock, Alluding To Potential Weakness - Moomoo
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? - Stocktwits
Viking Therapeutics (NASDAQ:VKTX) Stock in Focus Ahead of Cash-Burn Scrutiny, Earnings Set for July 29 - TechStock²
VKTX Stock Rises After-Hours: CNBC Flags Viking As Likely Buyout Target This Year As Big Pharma Hunts Next GLP-1 Winner - Stocktwits
Viking Therapeutics, Inc. Revenue Breakdown – DUS:1VT - TradingView
Viking Therapeutics Inc (VKTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Viking Therapeutics Inc (VKTX) Cash Flow - TradingKey
TradingKey - TradingKey
Viking Therapeutics Inc (VKTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Viking Therapeutics Inc (VKTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
VKTX Stock Draws Fresh Attention Ahead Of Earnings: Wall Street Sees Over 170% Upside As GLP-1 Race Burns Hot - Stocktwits
Viking Therapeutics Inc (VKTX) Institutional Confidence - TradingKey
VKTX|Viking Therapeutics Inc|Price:34.770|Chg%:-0.620 - TradingKey
VKTX Stock Clocks Best Day In Nearly 3 Months On Obesity Pipeline Optimism, Buyout Speculation - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Viking Therapeutics Inc (VKTX) Fundamental & Financial Data - Stocktwits
VKTX: Viking Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
Viking Therapeutics (VKTX.US) will release its earnings report after market close on July 29. - 富途牛牛
Viking Therapeutics Inc (VKTX) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Viking Therapeutics (VKTX) Stock Could Be Overvalued On Fresh Diabetes Therapy News - Yahoo Finance
Here's Why Viking Therapeutics, Inc. (VKTX) Fell More Than Broader Market - Yahoo! Finance Canada
Viking Therapeutics Announces Initiation of Phase 1 Study to Evaluate Novel Amylin Receptor Agonist VK3019 in Healthy Adults - AOL.com
Viking Therapeutics adds Dorothy Gemmell to board of directors By Investing.com - Investing.com South Africa
Viking Therapeutics adds Dorothy Gemmell to board of directors - Investing.com
Press Release: Viking Therapeutics Appoints Dorothy Gemmell to Board of Directors - Moomoo
Viking Therapeutics (VKTX) Appoints Dorothy Gemmell To Board As Commercial Focus Grows - Sahm
Viking Therapeutics to report Q2 2026 results on July 29 - scanx.trade
Viking Therapeutics to Report Financial Results for Second Quart - GuruFocus
Viking Therapeutics’ Q2 results arrive after markets close - Stock Titan
Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026 - Sahm
A New GLP-1 Challenger? Early Data Shows Viking's New Obesity Drug Tops Novo Rival - Stocktwits
(VKTX) Risk Channels and Responsive Allocation - Stock Traders Daily
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to C - GuruFocus
Kuehn Law Encourages Investors of Viking Therapeutics, Inc. to Contact Law Firm - Morningstar
Viking Therapeutics (VKTX) Stock Analysis: Biotechnology’s Hidden Gem with a 154% Potential Upside - DirectorsTalk Interviews
Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress - Stocktwits
VKTX Stock Outpaces LLY, ALT Ahead Of Earnings – Retail Eyes Breakout Ahead - Stocktwits
Investigation into Viking Therapeutics Officers for Fiduciary Breach - Intellectia AI
Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics Just Started Testing a Weight Loss Drug That Goes Beyond GLP-1 - The Motley Fool
VKTX Eyes Worst Week Since November As Trial Data Looms — Wall Street Still Sees 200% Upside - Stocktwits
Viking Therapeutics (NASDAQ:VKTX) stock maintains Phase 3 outlook despite 4.6% fall over the week - TechStock²
Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes." - The Motley Fool
Should You Buy Viking Therapeutics Stock on the Dip? Wall Street Is Screaming "Yes." - The Motley Fool
Viking Therapeutics Inc (VKTX) 財務データ
収益
当期純利益
現金流量
EPS
Viking Therapeutics Inc (VKTX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| ZANTE GREG | Chief Financial Officer |
Jul 29 '26 |
Sale |
33.47 |
21,217 |
710,141 |
212,204 |
| Mancini Marianna | Chief Operating Officer |
Jul 29 '26 |
Sale |
33.47 |
18,217 |
609,636 |
422,760 |
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):